China's homegrown COVID antiviral pill was included in the nation's medical subsidy program, health authorities said, after pricing talks broke down with Pfizer Inc. to cover its more expensive Paxlovid.
Caixin
China homegrown COVID pill included in national subsidy program
Price negotiations with Pfizer break down over more expensive Paxlovid
China approved Genuine Biotech’s Azvudine for adults with normal COVID symptoms under an emergency use authorization plan in July 2022.
Read Next
Latest on Caixin
